Confirm the Fungus Before You Treat the Nail.
Before you commit a patient to twelve weeks of systemic antifungal, confirm the organism — dermatophyte, yeast, or mold — in 24–48 hours.
Empirical terbinafine and oral itraconazole carry real hepatic risk, real cost, and three-month treatment commitments. Studies consistently show that 30–50% of nails clinically diagnosed as onychomycosis are negative on confirmatory testing — and KOH microscopy misses the rest.
Nine molecular targets covering dermatophytes, Candida, Aspergillus, and clinically relevant molds — confirmed in 24–48 hours from a nail clipping or skin scraping. Treat with confidence.
The clinical weight behind this panel.
Industry statistics from public-health bodies and peer-reviewed literature — context for why this testing matters.
PCR identifies the species — and detects co-infections culture misses.
Empiric therapy fails in non-dermatophyte molds.
Figures reflect publicly reported epidemiology and clinical literature for context only. They are not performance claims for the Chaseville Labs assay. See individual citations from the U.S. Centers for Disease Control and Prevention, World Health Organization, National Institutes of Health, and peer-reviewed journals.
Conditions, syndromes & infections covered.
The clinical scenarios where this panel is the right call — built around the differential your providers are actually working through.
Onychomycosis (Nail Fungus)
3The most common cause of toenail fungus — confirms fungal etiology before committing to 6–12 weeks of systemic antifungal.
More common in fingernails, paronychia, and immunocompromised hosts.
Aspergillus species, Fusarium oxysporum — increasingly recognized and frequently terbinafine-resistant.
Cutaneous Fungal Infections
3Trichophyton rubrum is the most common cause — interdigital, moccasin, and vesicular patterns.
Ringworm of the body, groin (jock itch), and scalp — common in athletes, children, and household contacts.
Hypopigmented or hyperpigmented patches on chest, back, and shoulders — often misdiagnosed as vitiligo or eczema.
Emerging & Resistant Fungi
3Emerging multidrug-resistant yeast — causes invasive infection in healthcare settings, hard to eradicate, and an infection-control nightmare.
Mold species causing onychomycosis, otomycosis, and (rarely from these sites) invasive disease in immunocompromised hosts.
Patient who has failed empirical antifungal and is still symptomatic.
9 targets, resolved from a single specimen.
Each organism below is reported individually as Detected, Not Detected, or Inconclusive — grouped here by pathogen class for clinical scanability.
Dermatophytes
2 targetsCandida
4 targetsAspergillus
2 targetsOther Molds
1 targetCulture was built for a different century.
Multiplex real-time PCR resolves what culture and rapid antigen miss — fastidious organisms, polymicrobial infections, viruses, and resistance markers — from a single specimen.
Culture & rapid antigen
- 3–5 daysPatient empirically treated before any answer arrives
- Misses fastidious & viral organismsNo growth ≠ no infection
- Single-organism biasPolymicrobial infections under-reported
- No resistance dataSusceptibilities arrive a day later, if at all
- Specimen-quality dependentPre-treated patients culture negative
Nail / Fungal on Bio-Rad CFX384
- 24–48 hoursMost reports back the next clinical day
- 9 targets, one runBacterial, viral, fungal, and parasitic in a single multiplex
- Detects what culture can'tFastidious organisms, viruses, and polymicrobial infections, all reported individually
- Validated LDTCLIA-certified, internally controlled, per-target Detected / Not Detected reporting
Per-target results, with clinical context.
Every analyte is reported individually as Detected, Not Detected, or Inconclusive. What a Detected result means clinically depends on which category the target falls into:
Dermatophyte detection (Trichophyton, Microsporum, Epidermophyton) confirms tinea unguium and supports oral terbinafine or itraconazole as first-line therapy.
Candida onychomycosis is more common in fingernails and immunocompromised hosts; C. auris detection warrants infection-control follow-up.
Aspergillus species cause non-dermatophyte mold onychomycosis that often resists terbinafine; itraconazole or combination therapy is typically preferred.
Malassezia, Fusarium, and Trichosporon detections explain treatment-refractory nail disease and direct species-specific antifungal selection.